- Home
- Investor Relations
- Curemark Announces the Addition of Stacy E Grant as the Senior Vice President of Corporate Strategy and Finance
- Curemark Announces the Key Addition of Dr. William R. McIntyre as Senior Vice President of Global Regulatory Affairs
- HUDSON VALLEY RENEGADES PARTNER WITH CUREMARK ON SENSORY SAFE SUITE
- Curemark Announces the Promotion of Chiwon Yang to Vice President of Manufacturing Sciences and Technology
- Curemark Announces The Appointment of Afia Asamoah To The Board of Directors
- Sensory Safe Suite to debut at PNC Field in 2021
- GALENAGEN’S CurePark HONORED AS ONE OF FAST COMPANY’S 2021 WORLD CHANGING IDEAS
- Curemark Announces The Appointment Of Leigh Morgan To The Board Of Directors
- CUREMARK Honored by Goldman Sachs for Entrepreneurship
- Galenagen Receives Patent for Remote Monitoring of Parkinson’s Disease
- Curemark Presents Preschool Population Data from Phase 3 Blüm Autism Study
- Curemark Completes Enrollment for its Phase 3 Clinical Trial for Children with Autism – The Blüm Study
- Dr. Joan Fallon, CEO of Curemark, Named EY Entrepreneur Of The Year® 2017 New York Award Winner
- Dr. Joan Fallon, CEO Of Curemark, Named EY Entrepreneur Of The Year® 2017 Award Finalist In New York
- Curemark Announces Further Expansion of Clinical Sites For Its Phase 3 Clinical Trial for Children with Autism – The Blüm Study
- BLÜM STUDY – A Phase 3 Clinical Trial for Children with Autism
- Deaconess Looking for Participants in Autism Clinical Trial
- Curemark and The Autism Society of America Announce Partnership
- Dr. Joan Fallon, Founder & CEO of Curemark, Named One of the 2016 PM360 Elite 100
- Curemark Celebrates World Autism Awareness Day as a Visionary Sponsor of Several Autism Speaks 2016 Walks
- Curemark CEO Dr. Joan Fallon To Be Featured Speaker At Two Scientific Conferences
- Jzaneen Lalani Joins Curemark as Chief Operating Officer
- Curemark CEO Joan Fallon To Present Power Talk At Athena Center For Leadership Studies September 29
- Curemark Secures $20 Million in Equity Financing
- Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism
- Curemark CEO Delivers Keynote Speech at Epigenetics Conference
- Curemark CEO Receives 2014 Gold Maverick of the Year Recognition at The Stevie Awards for Women in Business
- Curemark CEO To Receive Springboard Enterprises’ Northstar Award for “Visionary Leadership and Breakthrough Research in Autism”
- Curemark Named To The Red Herring Top 100
- Curemark CEO Joan Fallon To Speak at 2014 SXSW Interactive Festival
- Curemark Receives Worldwide Patent Coverage For Enzyme Delivery System
- Curemark Featured in Fast Company with Google & Purina (Nestle): Great Companies Solve Problems That Matter
- Curemark CEO, Dr. Joan Fallon, talks fund-raising and Curemark on Fox Business News
- Curemark Begins NDA Submission For CM-AT Autism Treatment
- Curemark Secures $18.5 Million Financing
- Curemark CEO To Deliver Keynote Address at the BioScience Vision Summit
- Curemark Enters into Research Collaboration with The Molecular Sciences Institute (VTT/MSI)
- Curemark Awarded New Patent For Treatment of Drug And Alcohol Addiction
- Curemark CEO Addresses White House Briefing on Life Sciences
- Curemark CEO, Dr. Joan Fallon, Talks Entrepreneurship and Innovation
- Curemark LLC Announces Positive Pre-NDA Meeting With FDA for New Drug Application for CM-AT for Autism
- Curemark CEO, Dr. Joan Fallon, talks with Entrepreneur Magazine
